Banner

Clinical Trials

Affinium Pharmaceuticals announces completion of recruitment for Phase 2 clinical trial of AFN-1252

Affinium Pharmaceuticals announced that full recruitment has been achieved in its multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections ("ABSSSI").

Read more...

Long-term efficacy and tolerability of Vimpat® (lacosamide)

UCB's antiepileptic drug (AED) Vimpat® (lacosamide) featured in several studies and analyses presented at the 62nd annual American Academy of Neurology (AAN) meeting. These data offer additional clinical evidence supporting the use of lacosamide as adjunctive therapy in the treatment of adult patients with partial-onset seizures.

Read more...

Anavex comments on failure of Pfizer and Medivation's Alzheimer's Investigational drug Dimebon

Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) issued a statement following the announcement from Pfizer and Medivation (NASDAQ:MDVN) that their investigational Alzheimer's drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials.

Read more...

Forest Laboratories, Inc. and Gedeon Richter Announce Results from a Phase IIb Study of Cariprazine

Forest Laboratories, Inc.Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia.

Read more...

Studies Published in The Lancet Show Roflumilast Improves Lung Function and Reduces Exacerbations

Forest Laboratories, Inc.Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.

Read more...

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

Schering-Plough Corp.Schering-Plough Corp., (NYSE: SGP) has announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.

Read more...

HemCon Medical Technologies, Inc. Announces Improved Results from Live Nail Infection Study

HemCon has announced results from an independent study investigating the time required to successfully treat fungal infected human nails which is a leading cause of Onychomycosis, the most common type of fungal nail infection. The studies were conducted as part of HemCon's continued program of development for a formulation based on its newest proprietary Mycosinate™ platform technology.

Read more...

World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Banner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

News in Pictures

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/9445461331.jpg

Abbott Launches New Psoriasisanswers.com Web site

August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/399322AstraZeneca_Headquarters.jpg

AstraZeneca Headquarters, London

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/280148roche_basel.jpg

Site Roche Basel

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/390839Gehry_Novartis.jpg

Gehry building, Novartis headquarters in Basel, Switzerland

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/240209GSK_Corporate.jpg

GSK Corporate HQ

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/200324sanofi_avenits.jpg

Sanofi-aventis Group head office

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/964792Boehringer_Ingelheim_Center.jpg

Boehringer Ingelheim Center, Ingelheim, Germany

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/164840Novo_Nordisk.jpg

Novo Nordisk's corporate headquarters in Bagsværd, Denmark

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth Read more

Be on top of World Pharma News
Want to place your Ads or News at the top of World Pharma News? Contact us now!